title: A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis.
abstract: Gliomas frequently display constitutive activation of the transcription factor STAT3, a protein that is known to be able to mediate neoplastic transformation. STAT3 regulates genes that play a central role in cellular survival, proliferation, self-renewal, and invasion, and a cohort of STAT3 target genes have been found that are commonly coexpressed in human cancers. Thus, these genes likely subserve the transforming ability of constitutively activated STAT3. To determine whether the coordinated expression of STAT3 target genes is present in a subset of human gliomas, and whether this changes the biology of these tumors in patients, gene expression analysis was performed in four distinct human glioma data sets for which patient survival information was available. Coordinate expression of STAT3 targets was significantly associated with poor patient outcome in each data set. Specifically, patients with tumors displaying high expression of STAT3 targets had a shorter median survival time compared to patients whose tumors had low expression of STAT3 targets. These data suggest that constitutively activated STAT3 in gliomas can alter the biology of these tumors, and that development of targeted STAT3 inhibitors would likely be of particular benefit in treatment of this disease.
authors: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
authors: James V
authors: JV
authors: Alvarez
authors: Neelanjan
authors: N
authors: Mukherjee
authors: Arnab
authors: A
authors: Chakravarti
authors: Pierre
authors: P
authors: Robe
authors: Gary
authors: G
authors: Zhai
authors: Abhijit
authors: A
authors: Chakladar
authors: Jay
authors: J
authors: Loeffler
authors: Peter
authors: P
authors: Black
authors: David A
authors: DA
authors: Frank
keywords: brain tumors; gene expression; signal transduction; transcription factors
references: Nature. 1985 Jan 10-18;313(5998):144-7
references: 2981413
references: Br J Cancer. 2001 Aug 17;85(4):518-22
references: 11506489
references: Oncogene. 2004 Apr 22;23(19):3308-16
references: 15064729
references: Nat Rev Cancer. 2002 Oct;2(10):740-9
references: 12360277
references: FASEB J. 2002 Jan;16(1):108-10
references: 11729097
references: Cancer Treat Res. 2003;115:267-91
references: 12613201
references: BMC Cancer. 2003 Sep 17;3:23
references: 13678425
references: Cancer Res. 1990 Oct 15;50(20):6683-8
references: 2208133
references: Cancer Res. 2003 Apr 1;63(7):1602-7
references: 12670911
references: Genes Dev. 2001 Jun 1;15(11):1311-33
references: 11390353
references: Cell. 2000 Jan 7;100(1):57-70
references: 10647931
references: Nature. 1992 Oct 29;359(6398):845-8
references: 1279432
references: Nat Rev Genet. 2001 Feb;2(2):120-9
references: 11253051
references: Science. 1997 Sep 12;277(5332):1630-5
references: 9287210
references: Blood. 2002 Jan 1;99(1):252-7
references: 11756179
references: Cancer Res. 2004 Sep 15;64(18):6503-10
references: 15374961
references: Bioinformatics. 2003 Feb 12;19(3):368-75
references: 12584122
references: Cell. 1999 Aug 6;98(3):295-303
references: 10458605
references: J Neuropathol Exp Neurol. 2006 Dec;65(12):1181-8
references: 17146292
references: Int J Cancer. 1995 Jan 17;60(2):168-73
references: 7829210
references: Cancer Res. 1990 Dec 15;50(24):8017-22
references: 2253244
references: Cell. 1996 Feb 9;84(3):331-4
references: 8608586
references: Clin Cancer Res. 2003 Jan;9(1):316-26
references: 12538484
references: Cancer Res. 2005 Jun 15;65(12):5054-62
references: 15958548
references: Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
references: 16199517
references: Cancer Cell. 2006 Oct;10(4):321-30
references: 17010675
references: Cancer Res. 2006 Mar 15;66(6):3162-8
references: 16540667
references: Cancer Biol Ther. 2004 Nov;3(11):1045-50
references: 15539936